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additional cardiovascular-risk-factors (ASCOT-LLA patients).
ASCOT-BPLA study compared 2 different antihypertensive
strategies (ATE+/-Bendroﬂumethiazide+/-Doxazosin) and AML
(+/-Perindopril+/-Doxazosin) to reduce cardiovascular events
in 19,257 hypertensive patients. AML demonstrated less all
cause mortality than ATE (p = 0.025). A sub-study (ASCOT-
LLA) comparing ATV to Placebo (PCB) in patients with
250 mg/dL was carried out. The ASCOT-LLA was early inter-
rupted because of a signiﬁcant reduction in the primary end-
point in favour of Atorvastatin. A factorial analysis of ASCOT-
LLA (ATV + AML; PBO + AML; ATV + ATE; PBO-ATE)
demonstrated a 53% relative risk reduction of ATV + AML
versus PBO + AML (p < 0.0001); and of 39% for ATV + AML
versus ATV + ATE (p = 0.016). METHODS: Two hypothetical
cohorts of ASCOT-LLA like patients were simulated for a 25
years time horizon under the perspective of the National Health
System, by a Markov model. Spanish costs (€2005) of ATV,
AML, ATE, Peridonpril and Bendroﬂumethiazide were taken
into account. Effects were based on results of the ASCOT 2x2
analysis: ATV + AML versus ATV + ATE. Results are expressed
as incremental cost-effectiveness ratio (ICER) per QALY. Costs
and effectiveness outcomes were discounted at a rate of 3%
and 5% per year, respectively. RESULTS: The basecase analysis
demonstrates that ATV + AML strategy is a more effective
alternative with an acceptable increase in costs: ICER
of ATV + AML was 17.334€ per QALY. CONCLUSION:
Atorvastatin + Amlodipine is a cost-effective strategy when
compared with Atorvastatin + Atenolol for the treatment of
hypertensive patients with no prior history of cardiovascular
disease, normal to mildly elevated cholesterol levels and with
at least 3 additional cardiovascular-risk-factors, being under
the threshold of 30.000€ per QALY usually accepted in our
environment.
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OBJECTIVES: To evaluate clinical and economic beneﬁt of
Drug Eluting Stents (DES) in comparison with Bare-Metal
Stents (BMS) and surgical treatment with coronary artery
bypass graft (CABG) for Sicily Regional Government.
METHODS: Cost-effectiveness analysis was carried out by two
decision models: patients treated with DES vs. BMS. Cost was
carried out from the point of view of the SSR (Servizio Sani-
tario Regionale, Regional Health Service). RESULTS: The use
of DES generated unitary differential savings of €9,003, after
9 months of follow-up, and total differential savings of
€4,114,371. The use of DES on patients destined to BMS gave
average unitary differential savings of €1,075, after 9 months of
follow-up, and average total differential savings of €927,875.
The use of DES instead of BMS and CABG allowed SSR to
make average differential savings of €3,735 per successful case.
A total of €2,476 represent the refund threshold value of DES,
setting to zero the SSR average differential savings for patients
treated with DES who would otherwise have been treated with
BMS. CONCLUSION: Results of the proposed models, tested
with sensitivity analysis, demonstrate the use of DES to be jus-
tiﬁed; moreover, these results could positively inﬂuence the atti-
tude of the SSR towards these new therapeutic strategies, which
are an improvement on standard therapies, both from a clinical
and a ﬁnancial standpoint.
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OBJECTIVES: Familial hypercholesterolemia (FH) is character-
ized by elevated LDL-Cholesterol and premature cardiovascular
disease. To evaluate the efﬁciency of preventive strategies, a
cost-effectiveness model was developed: treatment in real clinical
practice, different atorvastatin dosage in monotherapy 40 mg
(A40) or 80 mg (A80) and atorvastatin combined with Ezetimebe
10 mg (A40 + E10, A80 + E10). METHODS: A Markov model
under National Health System perspective and with a timeframe
of all life expectancy was developed. Spanish life tables (2002)
were modiﬁed with standard mortality rate for FH population
(1.59; IC-95% = 1.07–2.26) to convert the reduction of mortal-
ity into life years gained (LYG). Treatment effectiveness was
transformed in CV mortality reduction by using risk reduction
based on Framingham risk score. Statins, clinical management
and pharmacological costs were taken into account (Spanish
costs €2005). Costs and effectiveness were discounted at a rate of
6% and 3% per year, respectively. RESULTS: 1) Basecase sce-
nario (BS), based on Spanish FH database would represent 1.97
LYG per patient in comparison to no treatment, costs due statins
were €5.321, other management costs (MC) €23.389 and total
costs (TOC) €28710; 2) A40: 2.59 LYG, MC was reduced 4.5%
in comparison to BS; TOC were €30.569; 3)A80: 2.75 LYG,
reduction of MC:6.4%, and TOC: €30.133; 4)A40 + E10: 3.38
LYG, reduction of MC:14.3% and TOC: €36.104; and
5)A80 + E10: 3.62 LYG, reduction of CM: 17.6% and TOC:
€35.317. Management strategies from more to less efﬁcient incre-
mental cost-effectiveness rate (ICER) per LYG in comparison to
BS were: a) A80: €1.821; b) A40: €3.012; and c) A80 + E10:
€4.021; and d) A40 + E10: €5.250. CONCLUSION: Manage-
ment of FH with atorvastatin-based treatment is an efﬁcient
strategy: Atorvastatin 80 mg in monotherapy is the most efﬁ-
cient. If LDL therapeutic goals with Atorvastatin 80 mg are not
achieved, the concomitant use of Ezetimibe can give an addi-
tional effect with an acceptable incremental cost.
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OBJECTIVES: To evaluate the cost-effectiveness of atorvasta-
tin, rosuvastatin, and simvastatin in reducing LDL-cholesterol
(LDL-C) and in treatment of patients with high risk of fatal
cardiovascular disease to meet the European LDL-C target level
of 2.5 mmol/l. METHODS: The efﬁcacy of statins in terms of
mean percent reduction in LDL-C was determined by literature
review and Bayesian random effects meta-analysis. A simula-
tion model was created to evaluate the proportion of patients
treated to the LDL-C target (PTT) level of 2.5 mmol/l. The
uncertainty related to the independent variables was modeled
with Bayesian MCMC-simulation with the use of WinBUGS
software. The measures of cost-effectiveness were calculated by
annual medicine costs per PTT and by incremental cost-
effectiveness ratios (ICERs). The annual medicine costs were
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applied from Finnish medicine tariff. RESULTS: All the patients
with baseline LDL-C level of 4,0 mmol/l (SD = 0,25 mmol/l)
reached PTT when using rosuvastatin 10 mg, 20 mg or 40 mg.
Corresponding numbers for simvastatin 20 mg, 40 mg and
80 mg were 4%, 57%, and 99%, respectively. The incremental
annual cost of rosuvastatin 10 mg compared to generic simv-
astatin 40 mg was 710€ per additional PTT. When patient’s
baseline LDL-C level exceeded 4.2 mmol/l rosuvastatin pro-
duced the lowest annual medicine costs per PTT. With lower
levels of LDL-C simvastatin was the most cost-effective to use.
Atorvastatin was less effective and more costly than rosuvasta-
tin with all baseline LDL-levels and was therefore dominated.
CONCLUSION: The cost-effectiveness of statins depends on
patient’s cardiovascular risk proﬁle and baseline cholesterol
level. In Finland rosuvastatin is cost-effective in reaching Euro-
pean LDL-C target of 2.5 mmol/l when patient’s LDL-C level
exceeds 4.2 mmol/l.
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OBJECTIVES: Hypertension is an independent risk factor for
cardiovascular disease, which results in an enormous burden to
society, both in terms of health and costing. Therefore, health
gains and related cost-savings could be achieved by optimizing
antihypertensive treatment. The aim of this study was to esti-
mate the cost-effectiveness of treating patients with hyperten-
sion in The Netherlands with angiotensin II receptor blockers
(ARBs). METHODS: Our analysis comprised: 1) estimation of
the cost-effectiveness based on a published, prospective, ran-
domized, double-blind clinical trial comparing blood pressure
lowering of olmesartan, losartan, valsartan and irbesartan;
blood pressures at 8 weeks were inserted in the Framingham
risk functions to estimate cardiovascular complications,
using an international health economic model, and 2) a cost-
minimization analysis (assuming comparable effectiveness)
using daily practice prescription data from IADB.nl (50 phar-
macies), a database covering a population of 500,000.
RESULTS: After 8 weeks, the trial-based analysis showed that
with olmesartan versus losartan, valsartan, and irbesartan a
statistically signiﬁcant larger decrease in blood pressure was
achieved (11.5 versus 8.2, 7.9, and 9.9 mmHg [p < 0.05],
respectively). Furthermore, olmesartan resulted in most compli-
cations averted. Cost-effectiveness for olmesartan, losartan, val-
sartan, and irbesartan was estimated at €39,100, €77,100,
€70,700, and €50,900 per cardiovascular complication averted,
respectively. Pharmacy data showed that trial-dosing at 1
‘Deﬁned Daily Dose’ (DDD) was not found in practice. On
average, losartan, valsartan and irbesartan were consequently
dosed above 1 DDD varying from 1.19 to 1.38 ‘Prescribed
Daily Dose’ (PDD), whereas olmesartan was dosed at 0.88
PDD and thus presenting (relatively) lower costs. CONCLU-
SION: Olmesartan was estimated to be the most cost-effective
option of the four ARBs. However, due to differences found in
within-trial versus daily practice dosing and absence of effec-
tiveness data from daily practice, conﬁrmation is needed from
further prospective studies comparing ARBs based on compa-
rable blood pressure control including hard endpoints.
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OBJECTIVES: Despite considerable improvements in the treat-
ment of ST-elevated myocardial infarction (STEMI), patients
remain at long-term risk of additional cardiovascular (CV) events
(such as MI, stroke or vascular death). Over a four week treat-
ment period, the CLARITY-TIMI 28 and COMMIT/CCS-2 trials
demonstrated that clopidogrel (with and without loading dose,
respectively), administered in addition to standard therapy,
reduces the rate of mortality, infarct-related artery patency or MI
(RR 0.64 95% CI 0.53–0.76) and death, reinfarction or stroke
(0.91; 0.86–0.97), respectively. The aim of this study was to
assess the incremental cost per QALY (ICQ) of clopidogrel for
either one month or one year, in addition to standard care in
STEMI patients, from a UK perspective. METHODS: A cohort
Markov model described the experience of new CV events (MI
and stroke) prior to death in patients diagnosed with STEMI. UK
relevant STEMI baseline event rates were synthesised using data
from the literature and observational databases. Event rates in
clopidogrel patients were estimated by applying the aggregate
RRs from the respective trials to the baseline event rates. Health
state costs were derived from relevant UK-based costing studies
and updated to 2006 values, utility values were derived from the
broader literature. Costs and QALYs were discounted at 3.5%, a
full range of deterministic and probabilistic sensitivity analyses
were undertaken. RESULTS: For the 1-month and 1-year treat-
ment options both trials have mean ICQs below 2,500 and
4,000, respectively. In univariate sensitivity analyses the ICQ
never rose above 10,000. The probabilistic sensitivity analysis
showed that in all four analyses, clopidogrel was over 95% likely
to be cost-effective at a QALY value of 20,000. CONCLU-
SION: The estimated ICQs for both treatment options and for
both trials suggest that clopidogrel plus standard therapy is a
cost-effective alternative to standard therapy alone based on
current willingness to pay thresholds.
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OBJECTIVES: Ambulatory hypertension treatment is effective in
reducing mortality and morbidity due to cardiovascular diseases.
There are published evidences of under treatment of hyperten-
sion instead of the existing choice among lots of antihypertensive
medicines. This study aims to explore the antihypertensive medi-
cines prescribing and cost of hypertension therapy in Bulgaria
from the outpatient practice perspective. METHODS: A repre-
sentative sample of 2105 reimbursable prescriptions was col-
lected on a retrospective basis within one year. The prescriptions
were systematized according to the complexity of the therapy
(mono-, di-, three), INN, frequency of the prescribed brand
names of medicines, reimbursement drug prices, as well as,
patient co-payment. To calculate the cost of the outpatient
therapy was build the decision tree model. It matches the differ-
ences in the frequency of particular brand names prescribing and
their prices, as well as the cost dependence on complexity of the
therapy. RESULTS: The ACE inhibitors are the ﬁrst treatment
choice (41%, CI 95%) in the prescriptions, following by beta
blockers 19.43% and calcium channel blockers with 15.2%
share. The prescriptions with one medicine are 61%, di therapy
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